Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
106.17
+0.96 (0.91%)
At close: Aug 22, 2025, 4:00 PM
105.76
-0.41 (-0.39%)
After-hours: Aug 22, 2025, 7:49 PM EDT
Boston Scientific Revenue
Boston Scientific had revenue of $5.06B in the quarter ending June 30, 2025, with 22.84% growth. This brings the company's revenue in the last twelve months to $18.49B, up 21.44% year-over-year. In the year 2024, Boston Scientific had annual revenue of $16.75B with 17.61% growth.
Revenue (ttm)
$18.49B
Revenue Growth
+21.44%
P/S Ratio
8.47
Revenue / Employee
$348,943
Employees
53,000
Market Cap
157.32B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.75B | 2.51B | 17.61% |
Dec 31, 2023 | 14.24B | 1.56B | 12.29% |
Dec 31, 2022 | 12.68B | 794.00M | 6.68% |
Dec 31, 2021 | 11.89B | 1.98B | 19.92% |
Dec 31, 2020 | 9.91B | -822.00M | -7.66% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BSX News
- 13 days ago - Boston Scientific Corporation Is Expensive But Worth It - Seeking Alpha
- 15 days ago - Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025 - Seeking Alpha
- 16 days ago - Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions - Business Wire
- 22 days ago - 10 stocks favored to gain up to 30% in a sector that has missed this year's rally - Market Watch
- 4 weeks ago - Boston Scientific Corporation (BSX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Boston Scientific lifts annual profit view on steady heart devices demand - Reuters
- 4 weeks ago - Boston Scientific announces results for second quarter 2025 - PRNewsWire
- 4 weeks ago - How To Trade Boston Scientific Stock Ahead Of Its Upcoming Earnings? - Forbes